WHO Releases First Snapshot of AI in Healthcare Across 27 EU Nations

The World Health Organization's European Regional Office published a landmark report on April 20 providing the first comprehensive assessment of artificial intelligence adoption in healthcare across all 27 European Union member states. The findings reveal strong momentum, with every nation recognizing improved patient care as a driver of AI development and the majority already deploying AI tools in clinical settings.

The State of Play

The report, which represents the most extensive survey of its kind, found that AI adoption in European healthcare has accelerated dramatically since 2024. Across the EU, 63 percent of healthcare professionals now actively use AI in some capacity, while an additional 31 percent are piloting or evaluating AI initiatives, putting the healthcare sector ahead of most other industries where average AI adoption remains closer to 50 percent.

"This report demonstrates that AI in healthcare is no longer a future aspiration but a present reality across Europe," said Dr. Hans Kluge, WHO Regional Director for Europe. "The challenge has shifted from adoption to governance, ensuring these tools deliver equitable benefits while maintaining the highest standards of safety and ethics."

The most common applications include diagnostic imaging, where AI-powered tools assist radiologists in detecting anomalies in X-rays, CT scans, and MRIs; clinical decision support systems that help physicians identify potential drug interactions and recommend treatment protocols; and administrative automation that reduces the documentation burden on clinicians.

National Approaches Vary

While the overall trend is positive, the report reveals significant variation in how individual nations are approaching AI in healthcare. Nordic countries, particularly Finland and Denmark, lead in both adoption rates and regulatory frameworks. Germany and France have invested heavily in research infrastructure but face challenges in translating academic advances into clinical practice. Southern and Eastern European nations show lower adoption rates but are catching up quickly through EU-funded programs.

"The diversity of approaches across the EU is actually a strength," said Dr. Natasha Azzopardi Muscat, Director of Health Systems at WHO Europe. "Different countries are experimenting with different models, and the EU framework allows for rapid sharing of best practices across borders."

The report identified several common barriers to adoption, including concerns about data privacy under GDPR, a shortage of healthcare professionals with AI expertise, and the lack of standardized evaluation frameworks for clinical AI tools. Interoperability between national health systems and AI platforms remains a significant technical challenge.

Investment and Infrastructure

European investment in healthcare AI has grown substantially, though it still lags behind the United States and China in absolute terms. The EU's Horizon Europe program has allocated over 2 billion euros to AI health research through 2027, and several member states have launched national AI health strategies with dedicated funding.

The report recommends that member states establish national AI health registries to track deployed tools, invest in workforce training programs, and develop shared evaluation frameworks that can accelerate the path from research to clinical deployment.

Why This Matters

The WHO report arrives at a critical juncture for AI in healthcare. As AI tools move from pilot programs to routine clinical use, the questions shift from whether they work to how they should be governed, who bears liability when they fail, and how to ensure equitable access across different populations and healthcare systems.

The European approach, with its emphasis on regulation, equity, and cross-border coordination, offers a distinct model from the more market-driven approaches in the United States and China. The outcomes of this European experiment could influence global standards for healthcare AI governance.

What to Watch

The report sets a baseline for measuring progress in future years. Observers will be tracking whether the adoption rates continue to accelerate, whether the regulatory frameworks keep pace with technological change, and whether the early-adopter nations see measurable improvements in patient outcomes that justify the investment.